查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1848431

个人化基因组医学市场预测至2032年：按产品、给药方式、技术、应用、最终用户和地区分類的全球分析

Personalized Genomic Medicine Market Forecasts to 2032 - Global Analysis By Product (Diagnostics, Therapeutics, Preventive Medicine and Other Products), Mode of Delivery, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球个人化基因组医学市场预计到 2025 年将达到 6,639 亿美元，预计到 2032 年将达到 1,1452 亿美元，预测期内复合年增长率为 8.1%。

个人化基因组医学是一种前沿的医疗保健方法，可根据每个人的基因组成量身定制治疗和预防策略。透过分析个体的DNA，临床医生可以识别影响疾病风险、药物反应和治疗效果的基因变异。这有助于更精准的诊断、更有针对性的治疗和主动的健康管理，尤其对肿瘤学、罕见遗传疾病和药物基因组学领域影响深远。随着基因定序的普及和数据整合的改进，个人化基因组医学正在将传统的医疗模式转变为更精准、更具预测性、以患者为中心的系统，从而改善治疗效果并减少临床决策中的试验。

基因组定序技术的进步

基因组定序技术的进步是个人化基因组医疗市场的关键驱动力。次世代定序(NGS) 的创新使基因分析更快、更准确、更具成本效益。这些改进使临床医生能够识别致病突变并相应地制定治疗方案。随着定序仪越来越普及，其与常规临床工作流程的整合也日益广泛。准确解读复杂基因数据的能力正在彻底改变诊断、药物开发和预防医学，从而推动医疗保健和研究领域的发展。

基因组检测高成本

基因组检测的高成本仍是个人化基因组医疗市场发展的一大限制。儘管技术不断进步，但全面的DNA序列测定和分析仍需要昂贵的设备、熟练的人员以及复杂的数据解读。这些经济障碍限制了人们，尤其是在中低收入群体中，获得个人化基因组医疗服务的机会。保险覆盖范围和报销政策往往不一致，进一步限制了个人化基因组医疗的普及。在经济高效的解决方案和更高的可负担性得以实现之前，个人化基因组医疗的前景可能仍然遥不可及。

精准医疗的需求日益增长

精准医疗需求的不断成长为市场带来了巨大的机会。患者和医疗保健提供者越来越需要将遗传、环境和生活方式等因素纳入考虑的个人化治疗。基因组学洞察有助于实现标靶治疗，减少副作用并改善临床疗效。这种向个人化医疗的转变对肿瘤学、罕见疾病和药物基因组学产生了尤为显着的影响。随着认知度的提高和技术的进步，精准医疗正成为现代医疗保健的基石，推动基因组解决方案的投资和创新。

监管挑战

监管挑战威胁着个人化基因组医学市场的成长。基因资料的复杂性、伦理考量以及全球标准差异，对临床实施和商业化构成了障碍。基因组检测和治疗方法的核准流程冗长且不一致，可能会延迟创新解决方案的取得。资料隐私法和知情同意框架也存在很大差异，使跨境研究和病患参与变得复杂。解决这些监管问题对于确保基因组医学的安全、公平和可扩展应用至关重要。

COVID-19的影响：

COVID-19疫情凸显了遗传因素在疾病感受性和治疗反应中的重要性，加速了人们对个人化基因组医学的兴趣。基因组分析工具已被用于研究病毒-宿主相互作用、开发标靶治疗以及了解疫苗效力。这场危机凸显了对敏捷、数据驱动的医疗保健解决方案的需求，并推动了对基因组研究和基础设施的投资。疫情过后，医疗保健系统越来越多地采用个人化方法，以提高韧性和患者预后。预计这种转变将维持基因组医学市场的长期成长。

预计在预测期内，生物资讯学将成为最大的细分领域。

生物资讯学领域预计将在预测期内占据最大的市场份额，这得益于其在管理和解读复杂基因组数据方面的关键作用。生物资讯工具能够有效分析DNA序列、辨识疾病标记物并预测治疗反应。随着基因组资料集呈指数级增长，先进的演算法和软体平台对于临床决策至关重要。生物资讯学在诊断、药物开发和个人化医疗领域的应用正在迅速扩展，使其成为基因组医学的基本组成部分。

预计神经病学在预测期内的复合年增长率最高

预计神经病学领域将在预测期内实现最高成长率。这得归功于神经系统疾病遗传因素的研究日益增加。阿兹海默症、帕金森氏症和癫痫等疾病正透过基因组分析进行研究，以开发标靶治疗和早期诊断工具。神经病学的个人化治疗方案有望改善治疗效果并减缓疾病进展。随着认知度和资金投入的不断增加，基因组医学正成为神经系统治疗的核心，推动该领域的快速发展和创新。

占比最大的地区：

预计亚太地区将在预测期内占据最大的市场份额。这得益于医疗保健投资的增加、基因组学研究的拓展以及精准医疗需求的不断增长。中国、印度和日本等国家已启动国家级倡议，以推进基因组学基础设施建设并整合个人化医疗。该地区庞大的人口基数、日益加重的慢性病负担以及不断提升的数位医疗能力，共同构成了巨大的市场潜力。亚太地区在基因组学应用的采用和创新方面继续保持领先地位。

复合年增长率最高的地区：

北美地区预计将在预测期内实现最高的复合年增长率，这得益于其强大的科研基础设施、良好的法规结构和高昂的医疗保健支出。该地区拥有许多大型基因组学公司、学术机构和临床试验网络。对精准医疗的强劲需求、NGS的广泛应用以及支持性的报销政策进一步推动了该地区的成长。随着个人化医疗成为主流，北美将继续引领基因组学创新，塑造全球趋势和标准。

免费客製化服务：

订阅本报告的用户可享有以下免费客製化服务之一：

  • 公司简介
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业进行基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 原始研究资料
    • 二手研究资料
    • 先决条件

第三章 市场趋势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球个人化基因组医学市场（依产品划分）

  • 诊断
  • 治疗药物
  • 预防医学
  • 基因组资料解读工具
  • 其他产品

6. 全球个人化基因组医学市场（依交付类型）

  • 内部服务
  • 外包服务

7. 全球个人化基因组医学市场（依技术划分）

  • 次世代定序（NGS）
  • 聚合酵素链锁反应（PCR）
  • 微阵列
  • 基因编辑（CRISPR/Cas9）
  • 生物资讯学
  • 其他技术

8. 全球个人化基因组医学市场（依应用划分）

  • 肿瘤学
  • 心血管疾病
  • 神经病学
  • 感染疾病
  • 罕见遗传疾病
  • 药物基因组学
  • 其他用途

9. 全球个人化基因组医学市场（依最终用户划分）

  • 医院和诊所
  • 诊断实验室
  • 学术和研究机构
  • 製药和生物技术公司
  • 其他最终用户

第十章 全球个人化基因体医学市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 企业概况

  • Roche
  • Illumina
  • Thermo Fisher Scientific
  • Pfizer
  • Novartis
  • Qiagen
  • Foundation Medicine
  • GE Healthcare
  • Myriad Genetics
  • AstraZeneca
  • Exact Sciences
  • 23andMe
  • Biogen
  • IBM Watson Health
  • Decode Genetics
Product Code: SMRC31626

According to Stratistics MRC, the Global Personalized Genomic Medicine Market is accounted for $663.9 billion in 2025 and is expected to reach $1,145.2 billion by 2032 growing at a CAGR of 8.1% during the forecast period. Personalized genomic medicine is a cutting-edge approach to healthcare that tailors medical treatment and prevention strategies to an individual's genetic makeup. By analyzing a person's DNA, clinicians can identify genetic variations that influence disease risk, drug response, and treatment efficacy. This enables more accurate diagnoses, targeted therapies, and proactive health management. It is especially impactful in oncology, rare genetic disorders, and pharmacogenomics. As genomic sequencing becomes more accessible and data integration improves, personalized genomic medicine is transforming traditional care models into more precise, predictive, and patient-centered systems, enhancing outcomes and reducing trial-and-error in clinical decision-making.

Market Dynamics:

Driver:

Advancements in Genomic Sequencing Technologies

Advancements in genomic sequencing technologies are a key driver of the personalized genomic medicine market. Innovations in next-generation sequencing (NGS) have made genetic analysis faster, more accurate, and cost-effective. These improvements enable clinicians to identify disease-causing mutations and tailor treatments accordingly. As sequencing becomes more accessible, its integration into routine clinical workflows is expanding. The ability to decode complex genetic data with precision is revolutionizing diagnostics, drug development, and preventive care, fueling growth across healthcare and research sectors.

Restraint:

High Cost of Genomic Testing

High costs associated with genomic testing remain a major restraint in the personalized genomic medicine market. Despite technological progress, comprehensive DNA sequencing and analysis require expensive equipment, skilled personnel, and complex data interpretation. These financial barriers limit access, especially in low- and middle-income regions. Insurance coverage and reimbursement policies are often inconsistent, further restricting adoption. Until cost-effective solutions and broader affordability are achieved, the full potential of personalized genomic medicine may remain out of reach for many populations.

Opportunity:

Rising Demand for Precision Medicine

The rising demand for precision medicine presents a significant opportunity for the market. Patients and healthcare providers increasingly seek tailored treatments that consider genetic, environmental, and lifestyle factors. Genomic insights enable targeted therapies, reduce adverse drug reactions, and improve clinical outcomes. This shift toward individualized care is especially impactful in oncology, rare diseases, and pharmacogenomics. As awareness grows and technology advances, precision medicine is becoming a cornerstone of modern healthcare, driving investment and innovation in genomic solutions.

Threat:

Regulatory Challenges

Regulatory challenges pose a threat to the growth of the personalized genomic medicine market. The complexity of genetic data, ethical considerations, and varying global standards create hurdles in clinical implementation and commercialization. Approval processes for genomic tests and therapies can be slow and inconsistent, delaying access to innovative solutions. Data privacy laws and consent frameworks also vary widely, complicating cross-border research and patient engagement. Addressing these regulatory issues is essential to ensure safe, equitable, and scalable adoption of genomic medicine.

Covid-19 Impact:

The COVID-19 pandemic accelerated interest in personalized genomic medicine by highlighting the importance of genetic factors in disease susceptibility and treatment response. Genomic tools were used to study virus-host interactions, develop targeted therapies, and understand vaccine efficacy. The crisis underscored the need for rapid, data-driven healthcare solutions, boosting investment in genomic research and infrastructure. Post-pandemic, healthcare systems are increasingly integrating personalized approaches to improve resilience and patient outcomes. This shift is expected to sustain long-term growth in the genomic medicine market.

The bioinformatics segment is expected to be the largest during the forecast period

The bioinformatics segment is expected to account for the largest market share during the forecast period, due to its critical role in managing and interpreting complex genomic data. Bioinformatics tools enable efficient analysis of DNA sequences, identification of disease markers, and prediction of treatment responses. As genomic datasets grow exponentially, advanced algorithms and software platforms are essential for clinical decision-making. The integration of bioinformatics into diagnostics, drug development, and personalized care is expanding rapidly, making it a foundational component of genomic medicine.

The neurology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the neurology segment is predicted to witness the highest growth rate, due to increasing research into genetic factors underlying neurological disorders. Conditions such as Alzheimer's, Parkinson's, and epilepsy are being studied through genomic profiling to develop targeted therapies and early diagnostic tools. Personalized approaches in neurology offer hope for improved treatment outcomes and reduced disease progression. As awareness and funding grow, genomic medicine is becoming central to neurological care, driving rapid expansion and innovation in this segment.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to rising healthcare investments, expanding genomics research, and growing demand for precision medicine. Countries like China, India, and Japan are advancing genomic infrastructure and launching national initiatives to integrate personalized care. The region's large population base, increasing chronic disease burden, and improving digital health capabilities contribute to strong market potential. Asia Pacific continues to lead in adoption and innovation across genomic applications.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust research infrastructure, favorable regulatory frameworks, and high healthcare spending. The region is home to leading genomic companies, academic institutions, and clinical trial networks. Strong demand for precision therapies, widespread use of NGS, and supportive reimbursement policies further accelerate growth. As personalized medicine becomes mainstream, North America remains at the forefront of genomic innovation, shaping global trends and standards.

Key players in the market

Some of the key players in Personalized Genomic Medicine Market include Roche, Illumina, Thermo Fisher Scientific, Pfizer, Novartis, Qiagen, Foundation Medicine, GE Healthcare, Myriad Genetics, AstraZeneca, Exact Sciences, 23andMe, Biogen, IBM Watson Health, and Decode Genetics.

Key Developments:

In May 2025, Pfizer has entered into an exclusive global licensing agreement with 3SBio for SSGJ-707, a bispecific antibody targeting PD-1 and VEGF. This promising cancer therapy is undergoing clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. Under the agreement, Pfizer will pay 3SBio an upfront fee of $1.25 billion, with potential milestone payments up to $4.8 billion, and tiered royalties on sales.

In February 2025, Alloy Therapeutics and Pfizer have entered into a strategic collaboration to develop a novel antibody discovery platform aimed at targeting complex disease mechanisms. Leveraging Alloy's innovative technologies, the partnership seeks to enhance the development of effective antibody-based therapies.

Products Covered:

  • Diagnostics
  • Therapeutics
  • Preventive Medicine
  • Genomic Data Interpretation Tools
  • Other Products

Mode of Deliveries Covered:

  • In-House Services
  • Outsourced Services

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Gene Editing (CRISPR/Cas9)
  • Bioinformatics
  • Other Technologies

Applications Covered:

  • Oncology
  • Cardiovascular Diseases
  • Neurology
  • Infectious Diseases
  • Rare Genetic Disorders
  • Pharmacogenomics
  • Other Applications

End Users Covered:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Genomic Medicine Market, By Product

  • 5.1 Introduction
  • 5.2 Diagnostics
  • 5.3 Therapeutics
  • 5.4 Preventive Medicine
  • 5.5 Genomic Data Interpretation Tools
  • 5.6 Other Products

6 Global Personalized Genomic Medicine Market, By Mode of Delivery

  • 6.1 Introduction
  • 6.2 In-House Services
  • 6.3 Outsourced Services

7 Global Personalized Genomic Medicine Market, By Technology

  • 7.1 Introduction
  • 7.2 Next-Generation Sequencing (NGS)
  • 7.3 Polymerase Chain Reaction (PCR)
  • 7.4 Microarray
  • 7.5 Gene Editing (CRISPR/Cas9)
  • 7.6 Bioinformatics
  • 7.7 Other Technologies

8 Global Personalized Genomic Medicine Market, By Application

  • 8.1 Introduction
  • 8.2 Oncology
  • 8.3 Cardiovascular Diseases
  • 8.4 Neurology
  • 8.5 Infectious Diseases
  • 8.6 Rare Genetic Disorders
  • 8.7 Pharmacogenomics
  • 8.8 Other Applications

9 Global Personalized Genomic Medicine Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals and Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Academic and Research Institutes
  • 9.5 Pharmaceutical and Biotechnology Companies
  • 9.6 Other End Users

10 Global Personalized Genomic Medicine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Roche
  • 12.2 Illumina
  • 12.3 Thermo Fisher Scientific
  • 12.4 Pfizer
  • 12.5 Novartis
  • 12.6 Qiagen
  • 12.7 Foundation Medicine
  • 12.8 GE Healthcare
  • 12.9 Myriad Genetics
  • 12.10 AstraZeneca
  • 12.11 Exact Sciences
  • 12.12 23andMe
  • 12.13 Biogen
  • 12.14 IBM Watson Health
  • 12.15 Decode Genetics

List of Tables

  • Table 1 Global Personalized Genomic Medicine Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Genomic Medicine Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Personalized Genomic Medicine Market Outlook, By Diagnostics (2024-2032) ($MN)
  • Table 4 Global Personalized Genomic Medicine Market Outlook, By Therapeutics (2024-2032) ($MN)
  • Table 5 Global Personalized Genomic Medicine Market Outlook, By Preventive Medicine (2024-2032) ($MN)
  • Table 6 Global Personalized Genomic Medicine Market Outlook, By Genomic Data Interpretation Tools (2024-2032) ($MN)
  • Table 7 Global Personalized Genomic Medicine Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 8 Global Personalized Genomic Medicine Market Outlook, By Mode of Delivery (2024-2032) ($MN)
  • Table 9 Global Personalized Genomic Medicine Market Outlook, By In-House Services (2024-2032) ($MN)
  • Table 10 Global Personalized Genomic Medicine Market Outlook, By Outsourced Services (2024-2032) ($MN)
  • Table 11 Global Personalized Genomic Medicine Market Outlook, By Technology (2024-2032) ($MN)
  • Table 12 Global Personalized Genomic Medicine Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 13 Global Personalized Genomic Medicine Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 14 Global Personalized Genomic Medicine Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 15 Global Personalized Genomic Medicine Market Outlook, By Gene Editing (CRISPR/Cas9) (2024-2032) ($MN)
  • Table 16 Global Personalized Genomic Medicine Market Outlook, By Bioinformatics (2024-2032) ($MN)
  • Table 17 Global Personalized Genomic Medicine Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 18 Global Personalized Genomic Medicine Market Outlook, By Application (2024-2032) ($MN)
  • Table 19 Global Personalized Genomic Medicine Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 20 Global Personalized Genomic Medicine Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 21 Global Personalized Genomic Medicine Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 22 Global Personalized Genomic Medicine Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 23 Global Personalized Genomic Medicine Market Outlook, By Rare Genetic Disorders (2024-2032) ($MN)
  • Table 24 Global Personalized Genomic Medicine Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 25 Global Personalized Genomic Medicine Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 26 Global Personalized Genomic Medicine Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Personalized Genomic Medicine Market Outlook, By Hospitals and Clinics (2024-2032) ($MN)
  • Table 28 Global Personalized Genomic Medicine Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 29 Global Personalized Genomic Medicine Market Outlook, By Academic and Research Institutes (2024-2032) ($MN)
  • Table 30 Global Personalized Genomic Medicine Market Outlook, By Pharmaceutical and Biotechnology Companies (2024-2032) ($MN)
  • Table 31 Global Personalized Genomic Medicine Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.